Despite the broad availability of antidepressants and atypical antipsychotics approved to treat major depressive disorder (MDD), approximately one-third of these patients are treatment resistant (i.e., MDD patients who do not respond to two adequate course of antidepressants). The prevalence of treatment-resistant depression (TRD) has contributed to psychiatrists’ off-label use of ketamine (an anesthetic that can induce depressive symptom relief in TRD patients within hours of treatment administration) and to development of treatments with novel mechanisms of action that can address this cohort of patients’ depressive symptoms and provide rapid relief. Understanding psychiatrists’ clinical use of ketamine and expected use of late-phase emerging fast-acting antidepressants will help drug developers determine which clinical attributes their agents should target and future positioning in this market.
Additional Tools Available
Markets covered: United States
Primary research: Survey of 100 psychiatrists in United States
Key companies: Janssen, Allergan
Key drugs: ketamine, esketamine (Janssen), rapastinel (Allergan)
Key insights provided: